From 67% to 97%: That’s a big improvement

Point-of-sale edit upped % of Rx with <7 days supply

February 9, 2020

A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply

Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.

Short Acting Opioid Duration Edit Substantially Reduces Large Day Supply for Commercially Insured Opioid Naïve Members Compared to a Control Group without an Edit (Fall 2019)

Related news


March 30, 2023

Drug oversupply, or stockpiling, due to overlapping drug refills can cause unnecessary drug costs

If you have a chronic condition, your pharmacy may notify you advance of…


March 28, 2023

Biosimilars are at the door, Part 3

News about biosimilars is everywhere. Sometimes you just need the basics. This four-part…


March 27, 2023

Specialty Drug Pipeline Update: March 2023

This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…